The FDA has approved Zycubo (copper histidinate) injection as the first and only treatment of Menkes disease in pediatric ...

Credit: Getty Images. The FDA has issued a safety alert regarding the use of unapproved potassium phosphates drug products in pediatric patients. The Food and Drug Administration (FDA) has issued a ...

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~ The ...

The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

Please provide your email address to receive an email when new articles are posted on . Fears associated with needles may cause patients and caregivers to delay their use of epinephrine autoinjectors.

Please provide your email address to receive an email when new articles are posted on . Results showed the addition of a single-injection proximal sciatic nerve block to an adductor canal block ...

TARRYTOWN, N.Y., Oct. 21, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA ® ...

Mirna Chehade, MD, MPH, discusses the impact of adverse events on influencing treatment decisions for eosinophilic esophagitis (EoE) in pediatric patients, and considerations for the use of biologics.

Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease.